CTHRC1: A Biomarker for Evaluation of Rheumatoid Arthritis Disease Activity

Rheumatoid Arthritis Clinical Trial

Official title:

CTHRC1: A Biomarker for Evaluation of Rheumatoid Arthritis Disease Activity

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04415502
• Other study ID #: CTHRC1 in RA
• Status: Not yet recruiting
• Start date: October 1, 2020
• Est. completion date: May 1, 2021

Study information

• Verified date: June 2020
• Source: Assiut University
• Contact: Lobna Amer Araby Ahmed, Master
• Phone: 01019313530
• Email: Lobnaamer20[@]gmail.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of the study is to determine whether plasma levels of the collagen triple helix repeat containing (CTHRC1) protein can serve as a blood-based biomarker for diagnosis of rheumatoid arthritis (RA) ,and furthermore its correlation with disease activity

Description:

Rheumatoid arthritis (RA) is a chronic, progressive, autoimmune disease of synovial joints. Characterized by periods of flares with high disease activity involving both a systemic immune response and tissue-specific inflammatory events that can lead to erosive joint and bone destruction and subsequent disability . Currently, diagnosis of RA is based mainly on the extent of tenderness and swelling of the joints , levels of acute-phase reactants such as C-reactive protein (CRP) ,erythrocyte sedimentation rate(ESR) , high titers of rheumatoid factor (RF) and high titers of antibodies against cyclic citrullinated peptide (anti-CCP) in the plasma .Recently, reported increased levels of collagen triple helix repeat containing 1 protein (CTHRC1) are strongly associated with the severity of murine proteoglycan-induced arthritis and collagen antibody-induced murine arthritis (CAIA) , further CTHRC1 expression in murine experimental arthritis is increased in the synovium and specifically detected in activated murine , located at the synovial intimal lining and at the bone-pannus interface .Of interest,The expression pattern of CTHRC1 in pannus, its role in the function of FLS relevant to cartilage damage in RA, and CTHRC1's association with disease severity in murine arthritis raised the question of whether CTHRC1 could be used as a marker for RA diagnosis and monitoring of disease activity in patients .

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 100
• Est. completion date: May 1, 2021
• Est. primary completion date: April 1, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• patients diagnosed as RA

• age more than 18 years

Exclusion Criteria:

• other rheumatological diseases Malignancies Hepatic diseases

Related Conditions & MeSH terms

• Arthritis
• Arthritis, Rheumatoid
• Rheumatoid Arthritis

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Assiut University

References & Publications (2)

Chewick S. Infection control demand administrative support. Dimens Health Serv. 1975 Dec;52(12):40-1. — View Citation

Lumholtz IB. [Nurses' drug information: therapeutic action group: benzodiazepine derivatives. 2]. Sygeplejersken. 1975 Sep 24;75(38):15. Danish. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	CTHRC1 in RA	Measuring of CTHRc1 in Rheumatoid arthritis patients.	One year
Primary	CTHRc1 and RA disease activity	Correlation of CTHRc1levels with RA disease activity	One year